Skip to main content
. Author manuscript; available in PMC: 2021 Aug 16.
Published in final edited form as: Future Oncol. 2013 Dec 3;10(11):1827–1841. doi: 10.2217/fon.13.253

Figure 1. Cytotoxicity of tivozanib.

Figure 1.

(A) Cytotoxicity of tivozanib in KB-3-1 and KB-C2 cell lines. (B) Cytotoxicity of tivozanib in HEK293/pcDNA3.1 and HEK/ABCB1 cell lines. (C) Cell cytotoxicity of tivozanib in HEK293/pcDNA3.1, ABCG2-482-R2, ABCG2-482-T7 and ABCG2-482-G2 cell lines. The data points represent the mean ± standard deviation of triplicate determinations.